<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086032</url>
  </required_header>
  <id_info>
    <org_study_id>OBG-2556-02070</org_study_id>
    <nct_id>NCT02086032</nct_id>
  </id_info>
  <brief_title>The Effect of Different Types of Progestin on Sleeping of Menopausal Women</brief_title>
  <official_title>The Effect of Different Types of Progestin on Sleeping of Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators have found that sleeping disorder is an important problem in menopausal women.

      There have been papers reporting the effect of hormonal therapy on sleeping, but fews have
      reported the effect of different progestogens on sleeping quality. There is a need for more
      in-depth study and more conclusive evidence about the progestins which have the most
      beneficial effects on sleeping disorders in menopausal women.

      This study is going to collect the data from newly identified menopausal patients who are
      eligible for continuous estrogen-progestogen therapy for their climacteric treatment. The
      affects of the therapy will be monitored for 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New patients who are eligible for hormonal therapy will be selected.

      They will be allocated randomly into 2 different groups, each group being prescribed 1 of 2
      regimens of hormonal therapy:

        -  17 beta estradiol 1mg/day plus oral micronized progesterone 100mg/day

        -  17 beta estradiol 1mg/day plus dydrogesterone 10mg/day Patients will have their sleeping
           quality accessed using the Pittsburgh sleep quality index(PSQI) at their 1st visit and
           once a month for 3 months. The first and third PSQI score will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improving of sleeping quality (assessed by the PSQI score)</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The side effects comparing the 2 arms.</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
    <description>Acne,melanoma, breast tenderness, abnormal vaginal bleeding, weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The climacteric symptoms comparing the 2 arms.</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
    <description>self reported of hot flash, fatigue and weakness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Menopausal and Postmenopausal Disorders</condition>
  <arm_group>
    <arm_group_label>micronized progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg 17 beta-estradiol</intervention_name>
    <description>Comparing sleeping quality between micronized progesterone and dydrogesterone users.</description>
    <arm_group_label>micronized progesterone</arm_group_label>
    <arm_group_label>dydrogesterone</arm_group_label>
    <other_name>Estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <description>Comparing sleeping quality between micronised progesterone and dydrogesterone users.</description>
    <arm_group_label>dydrogesterone</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized progesterone</intervention_name>
    <description>Comparing sleeping quality between micronised progesterone and dydrogesterone users</description>
    <arm_group_label>micronized progesterone</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  new menopausal patients at Maharaj Nakorn Chiang Mai Hospital

          -  suitable for estrogen plus progesterone treatment

        Exclusion Criteria:

          -  contraindication for hormone replacement therapy

          -  recently used sleep enhancing medicine

          -  recently used psychotic medicine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawiwan Pantasri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Chiang Mai University, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrics and Gynecology department, Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>May 28, 2017</last_update_submitted>
  <last_update_submitted_qc>May 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Ekachai Leeangkoonsathian</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sleeping quality</keyword>
  <keyword>menopause</keyword>
  <keyword>climacteric</keyword>
  <keyword>progestin</keyword>
  <keyword>dydrogesterone</keyword>
  <keyword>micronized progesterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

